Figure 5.
Survival curves and event‐free survival of patients with pulmonary adenocarcinomas. Patients who were positive for OCIAD2 expression showed a favorable outcome (A, all cases; B, tumor diameter less than 2 cm) and (C) event‐free survival compared with patients who were negative for OCIAD2 expression.